Rifaximin Modifies Gut Microbiota and Attenuates Inflammation in Parkinson’s Disease: Preclinical and Clinical Studies

Rifaximin Modifies Gut Microbiota and Attenuates Inflammation in Parkinson’s Disease: Preclinical and Clinical Studies

Patients with Parkinson’s disease (PD) exhibit distinct gut microbiota, which may promote gut-derived inflammation. Rifaximin is a nonabsorbable antibiotic that can modify gut microbiota. The present study investigated the effect of rifaximin on gut microbiota and inflammation status in PD. The stud...

Full description

Bibliographic Details
Main Authors:	Chien-Tai Hong, Lung Chan, Kai-Yun Chen, Hsun-Hua Lee, Li-Kai Huang, Yu-Chen S. H. Yang, Yun-Ru Liu, Chaur-Jong Hu
Format:	Article
Language:	English
Published:	MDPI AG 2022-11-01
Series:	Cells
Subjects:	rifaximin gut microbiota Parkinson’s disease inflammation
Online Access:	https://www.mdpi.com/2073-4409/11/21/3468

Similar Items

Efficacy of rifaximin in the treatment of chronic relapsing diverticulitis
by: S. I. Achkasov, et al.
Published: (2012-04-01)

Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients
by: Kosuke Kaji, et al.
Published: (2020-03-01)

Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota
by: Ming-Wei Wang, et al.
Published: (2023-03-01)

Modulation of the microbiota across different intestinal segments by Rifaximin in PI-IBS mice
by: Shengyan Zhang, et al.
Published: (2023-01-01)

Rifaximin alleviates irinotecan-induced diarrhea in mice model
by: Chengyi Huang, et al.
Published: (2024-12-01)

Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori
Published: (2012-10-01)

Impact of crystal polymorphism of rifaximin on dissolution behavior
by: Imen Toukabri, et al.
Published: (2024-03-01)

The effects of rebamipide, sucralfate, and rifaximin against inflammation and apoptosis in radiation-induced murine intestinal injury
by: Won Moon, et al.
Published: (2022-12-01)

Rifaximin: An Option for the Treatment of Irritable Bowel Syndrome
by: Muhammad Abdul Quddus , Arslan Shahzad , Rukhsana Munawar , Khawaja Tahir Maqbool , Amna Mansoor , Naveed Gani , Sheikh Muhammad Taqqi Anwer
Published: (2021-12-01)

Highly Polymorphic Materials and Dissolution Behaviour: The Peculiar Case of Rifaximin
by: Annalisa Bianchera, et al.
Published: (2022-12-01)

Monoclonal antibody production and the development of a quantitative time-resolved fluoroimmunoassay for rifaximin in milk
by: Licai Ma, et al.
Published: (2019-01-01)

Rifaximin Treatment of Collagenous Colitis: A Randomised, Double-Blind, Placebo-Controlled Trial
by: Sabine Becker, et al.
Published: (2024-01-01)

Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice
by: Lianjun Yang, et al.
Published: (2019-03-01)

Advances in Therapy for Irritable Bowel Syndrome with Diarrhea: Role of Rifaximin in Combination with Metronidazole
by: Arif A Faruqui
Published: (2024-01-01)

Efficacy of Rifaximin Compared with Ciprofloxacin for the Treatment of Acute Infectious Diarrhea: A Randomized Controlled Multicenter Study
Published: (2010-09-01)

Novel therapeutic effects of rifaximin in combination with methylprednisolone for LPS-induced ‎oxidative stress and inflammation in mice‎: ‎An in vivo study
by: Marwa Salih ‎Al-Naimi, et al.
Published: (2024-12-01)

Determination of rifaximine in milk of dairy cows using High Pressure Liquid Chromatography (HPLC)
by: José Luis íngeles Manjarrez, et al.
Published: (2012-04-01)

Rifaximin: unique selective antibiotic for the treatment of gastrointestinal diseases
by: E. Yu. Plotnikova
Published: (2021-05-01)

Role of Rifaximin in Prevention of Recurrent Hepatic Encephalopathy in Chronic Liver Disease
by: Sahar Farzand, et al.
Published: (2020-12-01)

Managing Hepatic Encephalopathy - Combination of Lactulose and Rifaximin Versus Lactulose Monotherapy: A meta-analysis
by: Saad Khalid, et al.
Published: (2024-04-01)

Diverticular Disease and Rifaximin: An Evidence-Based Review
by: Anna Piccin, et al.
Published: (2023-02-01)

The effect of cyclic rifaximin therapy on symptoms of diverticular disease from the perspective of the gastroenterology outpatient clinic: a “real-life” study
by: Andrzej Moniuszko, et al.
Published: (2017-06-01)

Norfloxacin versus rifaximin for spontaneous bacterial peritonitis prophylaxis: A randomized controlled trial
by: Sanbanki Pala, et al.
Published: (2024-01-01)

Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier
by: Torre A, et al.
Published: (2023-10-01)

Cyclic rifaximin and soluble dietary fiber therapy for symptomatic diverticular disease: effective prevention of complications
by: E. V. Golovanova
Published: (2019-05-01)

Effectiveness and Safety of Rifaximin-Containing Regimens for Helicobacter pylori Eradication: Systematic Review – Are They Potential Eradication Regimens?
by: Wang Y, et al.
Published: (2022-07-01)

Rifaximin Protects against Malathion-Induced Rat Testicular Toxicity: A Possible Clue on Modulating Gut Microbiome and Inhibition of Oxidative Stress by Mitophagy
by: Nesreen Nabil Omar, et al.
Published: (2022-06-01)

Development of a Method for the Determination of Rifaximin and Rifampicin Residues in Foods of Animal Origin
by: Li-Ping Fan, et al.
Published: (2024-09-01)

Drug Utilization of Rifaximin-α in Patients with Hepatic Encephalopathy: Evidence from Real Clinical Practice in Italy
by: Valentina Perrone, et al.
Published: (2025-01-01)

Cyclic rifaximin therapy effectively prevents the recurrence of symptoms after exacerbation of symptomatic uncomplicated diverticular disease: a retrospective study
by: Anna M. Pietrzak, et al.
Published: (2019-03-01)

Eubiotic effect of rifaximin is associated with decreasing abdominal pain in symptomatic uncomplicated diverticular disease: results from an observational cohort study
by: Vladimir Ivashkin, et al.
Published: (2023-03-01)

Low dose rifaximin combined with N-acetylcysteine is superior to rifaximin alone in a rat model of IBS-D: a randomized trial
by: Gabriela Leite, et al.
Published: (2024-08-01)

Clinical experience with the use of the intestinal antibiotic Rifaximin for celiac disease
by: L. S. Оrеshkо, et al.
Published: (2019-10-01)

Russian Non-Interventional Study of the Efficacy and Tolerability of Rifaximin-α Therapy in Patients with Uncomplicated Diverticular Disease under the Conditions of Outpatient Practice
by: O. S. Shifrin, et al.
Published: (2020-04-01)

Preventive and therapeutic effects of rifaximin on hepatic encephalopathy with differential application dosages and strategies: a network meta-analysis
by: Guihua Fang, et al.
Published: (2024-03-01)

Effectiveness of rifaximin and fluoroquinolones in preventing travelers’ diarrhea (TD): a systematic review and meta-analysis
by: Alajbegovic Sanjin, et al.
Published: (2012-08-01)

The effect of rifaximin and lactulose treatments to chronic hepatic encephalopathy rats: An [18F]PBR146 in‐vivo neuroinflammation imaging study
by: Xiang Kong, et al.
Published: (2024-07-01)

A PK/PD model for the evaluation of clinical rifaximin dosage for the treatment of dairy cow mastitis induced by Escherichia coli
by: Honglei Wang, et al.
Published: (2023-01-01)

Rifaximin treatment in patients with severe alcoholic hepatitis: A multicenter, randomized controlled, open-label, pilot trial
by: Do Seon Song, et al.
Published: (2025-01-01)

Improved cognition after rifaximin treatment is associated with changes in intra- and inter-brain network functional connectivity
by: Franc Casanova-Ferrer, et al.
Published: (2024-01-01)